373 related articles for article (PubMed ID: 18957964)
1. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM.
Markert JM; Liechty PG; Wang W; Gaston S; Braz E; Karrasch M; Nabors LB; Markiewicz M; Lakeman AD; Palmer CA; Parker JN; Whitley RJ; Gillespie GY
Mol Ther; 2009 Jan; 17(1):199-207. PubMed ID: 18957964
[TBL] [Abstract][Full Text] [Related]
2. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.
Markert JM; Medlock MD; Rabkin SD; Gillespie GY; Todo T; Hunter WD; Palmer CA; Feigenbaum F; Tornatore C; Tufaro F; Martuza RL
Gene Ther; 2000 May; 7(10):867-74. PubMed ID: 10845725
[TBL] [Abstract][Full Text] [Related]
3. Phase ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication.
Aghi MK; Chiocca EA
Mol Ther; 2009 Jan; 17(1):8-9. PubMed ID: 19116635
[No Abstract] [Full Text] [Related]
4. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas.
Mineta T; Rabkin SD; Yazaki T; Hunter WD; Martuza RL
Nat Med; 1995 Sep; 1(9):938-43. PubMed ID: 7585221
[TBL] [Abstract][Full Text] [Related]
5. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses.
Markert JM; Razdan SN; Kuo HC; Cantor A; Knoll A; Karrasch M; Nabors LB; Markiewicz M; Agee BS; Coleman JM; Lakeman AD; Palmer CA; Parker JN; Whitley RJ; Weichselbaum RR; Fiveash JB; Gillespie GY
Mol Ther; 2014 May; 22(5):1048-55. PubMed ID: 24572293
[TBL] [Abstract][Full Text] [Related]
6. Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study.
Miller KE; Cassady KA; Roth JC; Clements J; Schieffer KM; Leraas K; Miller AR; Prasad N; Leavenworth JW; Aban IB; Whitley RJ; Gillespie GY; Mardis ER; Markert JM
Clin Cancer Res; 2022 Feb; 28(3):498-506. PubMed ID: 35105718
[TBL] [Abstract][Full Text] [Related]
7. Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy.
Todo T; Rabkin SD; Chahlavi A; Martuza RL
Hum Gene Ther; 1999 Nov; 10(17):2869-78. PubMed ID: 10584932
[TBL] [Abstract][Full Text] [Related]
8. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group.
Shand N; Weber F; Mariani L; Bernstein M; Gianella-Borradori A; Long Z; Sorensen AG; Barbier N
Hum Gene Ther; 1999 Sep; 10(14):2325-35. PubMed ID: 10515452
[TBL] [Abstract][Full Text] [Related]
9. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates.
Hunter WD; Martuza RL; Feigenbaum F; Todo T; Mineta T; Yazaki T; Toda M; Newsome JT; Platenberg RC; Manz HJ; Rabkin SD
J Virol; 1999 Aug; 73(8):6319-26. PubMed ID: 10400723
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors.
Todo T; Rabkin SD; Martuza RL
Cancer Gene Ther; 2000 Jun; 7(6):939-46. PubMed ID: 10880026
[TBL] [Abstract][Full Text] [Related]
11. Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus.
Todo T; Feigenbaum F; Rabkin SD; Lakeman F; Newsome JT; Johnson PA; Mitchell E; Belliveau D; Ostrove JM; Martuza RL
Mol Ther; 2000 Dec; 2(6):588-95. PubMed ID: 11124059
[TBL] [Abstract][Full Text] [Related]
12. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study.
Papanastassiou V; Rampling R; Fraser M; Petty R; Hadley D; Nicoll J; Harland J; Mabbs R; Brown M
Gene Ther; 2002 Mar; 9(6):398-406. PubMed ID: 11960316
[TBL] [Abstract][Full Text] [Related]
13. Augmentation of antitumor immune responses by multiple intratumoral inoculations of replication-conditional HSV and interleukin-12.
Iizuka Y; Suzuki A; Kawakami Y; Toda M
J Immunother; 2004; 27(2):92-8. PubMed ID: 14770080
[TBL] [Abstract][Full Text] [Related]
14. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.
Toda M; Iizuka Y; Kawase T; Uyemura K; Kawakami Y
Cancer Gene Ther; 2002 Apr; 9(4):356-64. PubMed ID: 11960286
[TBL] [Abstract][Full Text] [Related]
15. Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors.
Waters AM; Johnston JM; Reddy AT; Fiveash J; Madan-Swain A; Kachurak K; Bag AK; Gillespie GY; Markert JM; Friedman GK
Hum Gene Ther Clin Dev; 2017 Mar; 28(1):7-16. PubMed ID: 28319448
[TBL] [Abstract][Full Text] [Related]
16. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus.
Todo T; Rabkin SD; Sundaresan P; Wu A; Meehan KR; Herscowitz HB; Martuza RL
Hum Gene Ther; 1999 Nov; 10(17):2741-55. PubMed ID: 10584921
[TBL] [Abstract][Full Text] [Related]
17. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice.
Sundaresan P; Hunter WD; Martuza RL; Rabkin SD
J Virol; 2000 Apr; 74(8):3832-41. PubMed ID: 10729157
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas.
Friedman GK; Johnston JM; Bag AK; Bernstock JD; Li R; Aban I; Kachurak K; Nan L; Kang KD; Totsch S; Schlappi C; Martin AM; Pastakia D; McNall-Knapp R; Farouk Sait S; Khakoo Y; Karajannis MA; Woodling K; Palmer JD; Osorio DS; Leonard J; Abdelbaki MS; Madan-Swain A; Atkinson TP; Whitley RJ; Fiveash JB; Markert JM; Gillespie GY
N Engl J Med; 2021 Apr; 384(17):1613-1622. PubMed ID: 33838625
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic herpes simplex virus type-1 therapy in a highly infiltrative animal model of human glioblastoma.
Huszthy PC; Goplen D; Thorsen F; Immervoll H; Wang J; Gutermann A; Miletic H; Bjerkvig R
Clin Cancer Res; 2008 Mar; 14(5):1571-80. PubMed ID: 18316582
[TBL] [Abstract][Full Text] [Related]
20. Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial.
Prados MD; McDermott M; Chang SM; Wilson CB; Fick J; Culver KW; Van Gilder J; Keles GE; Spence A; Berger M
J Neurooncol; 2003 Dec; 65(3):269-78. PubMed ID: 14682377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
